TTA-A2

• CAT Number: I037583
• CAS Number: 953778-63-7
• Molecular Formula: C20H21F3N2O2
• Molecular Weight: 378.4
• Purity: 98%
• Synonyms: TTAA2; TTA A2; TTA-A2
• Target: Neuronal Signaling
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: (R)-2-(4-Cyclopropylphenyl)-N-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide
• InChI: InChI=1S/C20H21F3N2O2/c1-13(18-9-8-17(11-24-18)27-12-20(21,22)23)25-19(26)10-14-2-4-15(5-3-14)16-6-7-16/h2-5,8-9,11,13,16H,6-7,10,12H2,1H3,(H,25,26)/t13-/m1/s1
• InChIKey: GEYDMBNDOVPFJL-CYBMUJFWSA-N
• SMILES: O=C(N[C@@H](C1=NC=C(OCC(F)(F)F)C=C1)C)CC2=CC=C(C3CC3)C=C2

TTA-A2 (Cat.No:I037583) is a selective T-type calcium channel antagonist as a potent anticonvulsant that the Cav3.1 isoform plays a prominent role in mediating.

Reference

1: Cazade M, Nuss CE, Bidaud I, Renger JJ, Uebele VN, Lory P, Chemin J. Cross-modulation and molecular interaction at the Cav3.3 protein between the endogenous lipids and the T-type calcium channel antagonist TTA-A2. Mol Pharmacol. 2014 Feb;85(2):218-25. doi: 10.1124/mol.113.089581. Epub 2013 Nov 8. PubMed PMID: 24214826.
2: Kraus RL, Li Y, Gregan Y, Gotter AL, Uebele VN, Fox SV, Doran SM, Barrow JC, Yang ZQ, Reger TS, Koblan KS, Renger JJ. In vitro characterization of T-type calcium channel antagonist TTA-A2 and in vivo effects on arousal in mice. J Pharmacol Exp Ther. 2010 Nov;335(2):409-17. doi: 10.1124/jpet.110.171058. Epub 2010 Aug 3. PubMed PMID: 20682849.